Table 1.
Characteristics of patients.
| Entire patient population | (n) | |
|---|---|---|
| Total number of patients included (n) | 258 | |
| Seminoma (n; % of all) | 189 | 73.3% |
| Nonseminoma (n; % of all) | 69 | 26.7% |
| Median age at diagnosis (years; IQR; range) | 36 | 31–44; 18–70 |
| Median duration of follow-up (months; IQR; range) | 18 | 9–27; 3–48 |
| Total number of M371 measurements (n) | 1179 | |
| Relapsing patients | (n) | |
| Number of relapses (n; % of all) | 39 | 15.1% |
| Number of relapsing seminoma (n; % of all relapses) | 17 | 43.6% |
| Number of relapsing nonseminoma (n; % of all relapses) | 22 | 56.4% |
| Median interval to relapse, all patients (months; IQR) | 6 | 3–12 |
| Median interval to relapse, seminoma patients (months; IQR) | 9 | 3–18 |
| Median interval to relapse, nonseminoma patients (months; IQR) | 6 | 3.75–9 |
| Median age of all relapsing patients (years; IQR) | 36 | 26–43 |
| Median age of relapsing seminoma patients (years; IQR) | 36 | 30–56 |
| Median age of relapsing nonseminoma patients (years; IQR) | 34.5 | 24.25–40.75 |
| Elevation of bHCG at relapse (n elevated/N eligible; % of eligible) | 11/31 | 35.5% |
| Elevation of AFP at relapse (n elevated/N eligible; % of eligible) | 8/32 | 25.0% |
| Elevation of bHCG/AFP at relapse (n elevated/N eligible; % of eligible) | 14/31 | 45.2% |
| Elevation of M371 at relapse (n elevated/N eligible; % of eligible) | 39/39 | 100% |
AFP/bHCG: elevation of bHCG or AFP or of both.